Trial Profile
Effects of empagliflozin vs omarigliptin on beta-cell function in patients with type 2 diabetes: an open-label randomized controlled study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 May 2020
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Omarigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EVOLB study
- 21 Feb 2019 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 New trial record